Sun.Jan 05, 2025

article thumbnail

Biological Characterization of One Oxadiazole Derivative (5(4‐Hydroxyphenyl)‐2‐(N‐Phenyl Amino)‐1,3,4‐Oxadiazole): In Vitro, In Silico, and Network Pharmacological Approaches

Chemical Biology and Drug Design

5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. ABSTRACT Oxadiazole compounds are of great interest because they have a range of biological activities ranging from antioxidants to anticancer agents. Against this background, we wanted to demonstrate the antioxidant, enzyme inhibitory, and anticancer effects of 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole (Hppo).

article thumbnail

Edwin Cohn and the Harvard Blood Factory

Codon

Today we launch Issue 05 of Asimov Press. Read our full Editors’ Note and preview upcoming articles on our website. Thanks for reading! Edwin Cohn, a temperamental and entrepreneurial protein chemist working at Harvard University in the early 1900s, is perhaps one of the most underrated translational scientists of all time. In 1940, with the likelihood of America’s involvement in World War II steadily rising, the U.S. military approached Cohn about developing medical products from bl

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Final Rule for ACNU Arrives in Time for End of Year but Not Much New to Celebrate

FDA Law Blog: Biosimilars

By Deborah L. Livornese As promised in the Fall Unified Regulatory Agenda, FDA issued the final rule to establish the pathway to obtain marketing approval of a nonprescription drug product with an additional condition for nonprescription use (ACNU) on December 26, 2024, before the end of the calendar year. 89 Fed. Reg. 105288 (Dec. 26, 2024). We described the 2022 proposed rule and the ten-plus year history leading up to its issuance in our blog post here.

FDA 59
article thumbnail

Understanding External Credentials and Named Credentials in Salesforce

Perficient: Drug Development

Imagine this: youre on a treasure hunt. The treasure is hidden in a locked vault, and to open it, you need the right key. In Salesforce, when you need to access external systems, the key is what we call External Credentials and Named Credentials. But what exactly are they? Lets dive into this journey together and unravel their secrets in a simple and beginner-friendly way.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Dexmedetomidine Inhibits Ferroptosis by Regulating the SRY‐Box Transcription Factor 9/Divalent Metal Transporter‐1 Axis to Alleviate Cerebral Ischemia/Reperfusion Injury

Chemical Biology and Drug Design

Dex decreased SOX9 expression and then reduced the transcriptional activation of DMT1, ameliorating ferroptosis to improve cerebral ischemia/reperfusion injury. ABSTRACT Cerebral ischemia/reperfusion injury (IRI) is pathologically associated with ferroptosis. Dexmedetomidine (Dex) exerts neuroprotective activity after cerebral IRI. Our work focused on probing the pharmacologic effect of Dex on ferroptosis during cerebral IRI and the mechanisms involved.

article thumbnail

Conditional Rendering in LWC Gets a Modern Upgrade!

Perficient: Drug Development

Big news, Trailblazers! If youve ever worked with Lightning Web Components (LWC) , youve likely used the good old if:true and if:false directives for conditional rendering. These directives have served us well, but Salesforce has introduced a much-needed upgrade! Say hello to the modern conditional rendering directives : lwc:if, lwc:elseif, and lwc:else.

52